The protolerogenic properties of VDR agonists, as discussed above, render them suitable candidates as immunosuppressants for either autoimmune diseases or graft rejection, as clearly summarized by Mathieu and Adorini, since quite ago [94]. The gene discussed is VDR; the disease is autoimmune disease.